Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.37 |
| ▸ | CA12 | O43570 | 9/20 | 0.37 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.36 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.31 |
| ▸ | PTPRC | P08575 | 1/20 | 0.31 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7117234 | 0.88 | CTNNB1 (0.36) | CA2CA12MRGPRX4ADRB3 | |
| SCHEMBL6734434 | 0.87 | LY96 (0.35) | CA2CA12MRGPRX4FFAR1ADRB3 | |
| SCHEMBL6740455 | 0.87 | CXCR2 (0.38) | CA2CA12CXCR2CXCR1MRGPRX4 | |
| SCHEMBL7127966 | 0.86 | ATM (0.35) | CA2CA12MRGPRX4ADRB3 | |
| SCHEMBL6738238 | 0.79 | MMP2 (0.37) | MRGPRX4 | |
| SCHEMBL6738240 | 0.79 | MMP2 (0.37) | MRGPRX4 | |
| SCHEMBL6732763 | 0.77 | SIGMAR1 (0.34) | CA2CA12MRGPRX4 | |
| SCHEMBL7126321 | 0.76 | NPR3 (0.39) | — | |
| SCHEMBL7059153 | 0.74 | CYP2A6 (0.38) | MRGPRX4ADRB3 | |
| SCHEMBL7116976 | 0.74 | MMP2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | SMITHKLINE BEECHAM P.L.C. | 2004-11-11 | — | — | US | disclosed |
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199571-A1 | (Hetero) Bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives | CD40, CD22, CD2 | CA2 673/4885CA12 165/4885CXCR2 420/4885 |
| US-20040225006-A1 | (Hetero) bicyclymethanesulfonylamino-substituted hydroxamic acid derivates | CD40, TNFRSF1A, CD2 | CA2 1138/4885CA12 301/4885CXCR2 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.